Navigation Links
Neose Announces Presentation of Positive Preclinical Data on,GlycoPEGylated Factor VIIa at the XXI Congress of the International,Society on Thrombosis and Haemostasis

HORSHAM, Pa.--(BUSINESS WIRE)--Jul 11, 2007 - Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that two poster presentations were presented with its collaborative partner, Novo Nordisk A/S, relating to GlycoPEGylated recombinant Factor VIIa at the XXIst Congress of the International Society on Thrombosis and Haemostasis in Geneva, Switzerland. The data presented demonstrates that GlycoPEGylation(TM) significantly prolongs the active half-life of rFVIIa. GlycoPEGylated Factor VIIa, currently in Phase I, is being developed by Novo Nordisk A/S under a license from Neose.

The posters, which were co-authored by Novo Nordisk and Neose, are titled:

-- Development of long-acting rFVIIa derivatives by GlycoPEGylation(TM)

-- Effect of GlycoPEGylation(TM) on the pharmacokinetic properties of rVIIa

The full poster presentations are available on the Neose corporate website at: http://phx.corporate-ir.net/phoenix.zhtml?c=60494&p=irol-presentations

About Coagulation Factor VII

Factor VII/VIIa is used in the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients with congenital hemophilia with inhibitors to coagulation factors VIII or IX. The worldwide market for recombinant Factor VII was approximately $1 billion in 2006, with Novo Nordisk being the only participant.

About Neose Technologies, Inc.

Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market, on its own and through strategic partnerships. The lead candidates in its pipeline, NE-180 for use in the treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure and GlycoPEG-GCSF for chemotherapy-induced neutropenia, target markets with aggregate sales in excess of $15 billion. For more information, please visit www.neose.com.

Neose "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statement, see the sections of Neose's Annual Report on Form 10-K for the year ended December 31, 2006, entitled "Risk Factors" and "Special Note Regarding Forward-Looking Statements" and discussions of potential risks and uncertainties in Neose's subsequent filings with the SEC.

Contact

Neose Technologies, Inc.
A. Brian Davis
Sr. Vice President and Chief Financial Officer
215-315-9000
or
Barbara Krauter
Manager, Corporate Communications
215-315-9004


'"/>




Related medicine technology :

1. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... LOS ANGELES , Feb. 5, 2016  Redwood ... of a new product designed to help women balance ... oral strip delivery technology. Jason Cardiff ... company will be able to help the millions of ... suffer from the effects of imbalanced hormones. Our research ...
(Date:2/5/2016)... -- ivWatch, a medical devices company, is one of five recipients ... Terry McAuliffe,s office. ivWatch will be receiving the ... event to be held at the Science Museum of ... business that have made significant contributions to science. ... ...
(Date:2/5/2016)... in Alabama seeking prostate care with ... have to travel out of state. Vituro Health ... of Alabama to provide a total prostate management program ... Alabama is known throughout the ... using many different modalities. They are the largest and one ...
Breaking Medicine Technology:
(Date:2/8/2016)... , ... February 08, 2016 , ... ... its newly redesigned website, federallabs.org . The site houses a wealth of ... available federal technologies through the process called technology transfer (T2). As a network ...
(Date:2/8/2016)... ... ... famous for gift giving with flowers, chocolates and other tokens of affection meant to remind ... than 5.6 million Americans suffering with Alzheimer’s, those store bought gifts - no matter ... they’ve led and the people they’ve touched. , That’s why Give To ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... and clothing, announced expansion into Canada to provide its range of unique and ... sales office in Quebec City that will provide bilingual customer service and marketing ...
(Date:2/8/2016)... , ... February 08, 2016 , ... Delta Dental of ... help combat pancreatic cancer. , Gary D. Radine, who recently retired as president and ... American Cancer Society’s 2015 CEO of the Year , helped lead the effort ...
(Date:2/8/2016)... ... 08, 2016 , ... FileHold's document management software has been ... cloud hosted environment for FileHold software that is pay per user subscription-based and ... using the FileHold web services API. DocuSyst also advises clients on fully functioning ...
Breaking Medicine News(10 mins):